Genocea Biosciences Inc (NASDAQ:GNCA) Given Consensus Recommendation of “Buy” by Analysts

Genocea Biosciences Inc (NASDAQ:GNCA) has been given a consensus rating of “Buy” by the six research firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $16.33.

Several brokerages recently commented on GNCA. Zacks Investment Research upgraded shares of Genocea Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of Genocea Biosciences in a report on Tuesday, June 23rd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $10.00 price target on shares of Genocea Biosciences in a report on Tuesday, May 12th.

NASDAQ:GNCA traded down $0.11 during mid-day trading on Friday, hitting $2.19. 250,300 shares of the stock traded hands, compared to its average volume of 327,499. The stock has a market capitalization of $63.58 million, a price-to-earnings ratio of -1.43 and a beta of 2.35. Genocea Biosciences has a 52 week low of $1.10 and a 52 week high of $4.03. The firm’s 50 day moving average is $2.52 and its two-hundred day moving average is $2.17. The company has a quick ratio of 1.98, a current ratio of 1.98 and a debt-to-equity ratio of 1.28.

Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings results on Thursday, April 30th. The biotechnology company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.11). As a group, research analysts predict that Genocea Biosciences will post -1.56 EPS for the current year.

Hedge funds have recently modified their holdings of the business. Oxford Asset Management LLP bought a new position in Genocea Biosciences in the 4th quarter worth about $27,000. WINTON GROUP Ltd bought a new position in Genocea Biosciences in the 1st quarter worth about $30,000. Bank of New York Mellon Corp bought a new position in Genocea Biosciences in the 1st quarter worth about $35,000. Renaissance Technologies LLC grew its stake in Genocea Biosciences by 37.4% in the 4th quarter. Renaissance Technologies LLC now owns 279,511 shares of the biotechnology company’s stock worth $579,000 after acquiring an additional 76,149 shares in the last quarter. Finally, FNY Investment Advisers LLC grew its stake in Genocea Biosciences by 9.1% in the 1st quarter. FNY Investment Advisers LLC now owns 300,000 shares of the biotechnology company’s stock worth $516,000 after acquiring an additional 25,000 shares in the last quarter. Institutional investors and hedge funds own 50.27% of the company’s stock.

About Genocea Biosciences

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

See Also: Trading Strategy Methods and Types

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.